Loading...
For new treatments to become accessible in Canada, they first need to go through a clinical trial in Canada. If you are interested in participating in a clinical trial, please visit our Clinical Trials page to learn about the current opportunities in Canada.

Treatments currently undergoing trials in Canada

CSL-312 (Garadacimab): is a novel Factor XIIa-inhibitory monoclonal antibody (FXIIa mAb) currently in Phase 2 clinical development as a new type of once-monthly subcutaneous prophylactic treatment for attacks related to HAE, a form of bradykinin-mediated angioedema.

CSL Behring

Clinical Trial Info

News Article

KVD-900 (Sebetralstat): a potential oral, on-demand therapy for hereditary angioedema attacks that is designed to inhibit kallikrein.

KalVista Pharmaceuticals

KONFIDENT Clinical Trial

News Article

KVD-824: is an investigational oral medication designed to prevent HAE attacks by inhibiting the activation of plasma kallikrein.

KalVista Pharmaceuticals

KOMPLETE Clinical Trial

News Article

PHVS 416: is a softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor being developed to provide rapid exposure of attack-mitigating medicine in a small oral dosage form.

Pharvaris

RAPIDe-1 Clinical Study

Company Press Release

PHVS 416: is an extended-release tablet formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor being developed to provide sustained exposure of attack-preventing oral medicine.

Pharvaris

HAE CHAPTER-1 Clinical Study

Company Press Release

Further treatments in development:

 ATN-249: is a novel, potent, selective, and orally-administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema.

Attune Pharmaceuticals

Company Press Release

BMN-311: An investigational gene therapy intended to provide C1 esterase inhibitor to treat hereditary angioedema.

BioMarin

News Article

NTLA-2002 is a single-dose investigational treatment for the potential to continuously reduce kallikrein activity and prevent attacks in people living with hereditary angioedema (HAE).

Intellia Therapeutics

Company Press Release

PKK-L Rx is an investigational antisense medicine designed to reduce the production of prekallikrein, or PKK, which plays a key role in the activation of inflammatory mediators associated with acute attacks of HAE.

Ionis Pharmaceuticals

Company Press Release

STAR-0215: is a monoclonal antibody inhibitor of plasma kallikrein designed to provide attack prevention for HAE.

Astria Therapeutics

News Article

Adeno Assisted Vector Gene Therapy: designed to deliver a gene encoding therapeutic antibody that binds to plasma kallikrein.

REGENXBIO

Company Press Release